Table 3
Annual rate of decline in post-bronchodilator FEV1 by treatment allocation
| Study | Annual change in FEV1 (ml/year) | Reduction in annual change in FEV1 (ml/year) | |
|---|---|---|---|
| Placebo | Steroid | ||
| All data mean (SE) except where SE not reported or calculable (*) or where median values reported (†, see text) | |||
| NR=not reported; FEV1 =forced expiratory volume in 1 second. | |||
| Burge et al7 | −59 (4.4) | −50 (4.1) | 9.0 (6.0) |
| Lung Health Study Research Group5 | −47.0 (3.0) | −44.2 (2.9) | 2.8 (4.2) |
| Pauwels et al10 | −60† | −46.7† | 13.3 (6.8)† |
| van Grunsven et al19 | NR | NR | 39.0 (23.0) |
| Vestbo et al12 | −49.1* | −46.0* | 3.1 (8.1) |
| Weir et al9 | −56.9 (15) | −20.6 (16) | 36.3 (22.3) |
